ITOS News and Press, iTeos Therapeutics Inc. From 09/08/20

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 08, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, to...

iTeos Therapeutics (NASDAQ: ITOS ) : Q2 GAAP EPS of -$29.49. More news on: iTeos Therapeutics, Inc., Earnings news and commentary, Read more ...

- July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 - - EOS-850 A 2A R antagonist and EOS-448 FC g R-enabled anti-TIGIT antibody continue to progress in clinical trials - CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2020 (GLOBE NEWSW...

In July 2020, the market has gained steam again, with the S&P 500 ( SPY ) going up 5.51% despite a deterioration in the weekly jobless claims and an increase in US COVID-19 deaths. However, insiders are not buying into this recovery, with total US insider purchasing activity reaching h...